{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Currently, patients with moderately to severely active RA are often treated with cDMARDs,', 'with MTX being the most commonly used. For patients with an inadequate response to', 'cDMARDs, biologic agents that inhibit TNF-a, especially in combination with MTX, are', 'indicated (Smolen et al, 2014). Nonetheless, a substantial proportion of patients receiving', 'biologics (i.e., approximately 40% to 50% of those receiving TNFi therapy) have inadequate', 'response to such treatment (Marchesoni et al, 2009; Rubbert-Roth and Finckh, 2009;', 'Cohen et al, 2008). Thus, there is an unmet need for new therapeutic approaches utilizing', 'alternative modes of action in this patient population.', 'Olokizumab is being developed to address the unmet needs of patients with these severe,', 'progressive, and debilitating disorders through a different therapeutic approach, utilizing an', 'alternative mode of action. Within the class of therapeutic antibodies targeting the', 'IL-6 pathway, OKZ is anticipated to be more potent because of its high affinity for IL-6 and', 'its axis of intervention (inhibiting the interaction between IL-6 and gp 130). Also, since OKZ', 'is of the Ig G4 isotype, it would not be expected to mediate significant levels of', 'antibody-mediated complement fixation or cell-mediated cytotoxicity.', 'Olokizumab is being developed for the treatment of RA to reduce signs and symptoms of', 'disease and improve physical functioning. The proposed indication for OKZ is to be used in', 'combination with MTX for the treatment of moderately to severely active RA in adult', 'patients who have been inadequately controlled by MTX treatment or previous TNFi', 'treatment.', \"Refer to the most recent version of the Investigator's Brochure for additional information on\", 'OKZ, including:', 'In vitro activity', 'Nonclinical pharmacokinetics (PK) and product metabolism', 'Nonclinical pharmacology and toxicology', 'Pharmacokinetics, efficacy, and safety profile in clinical studies', '2.2.2', 'Nonclinical Development', 'Nonclinical studies have shown that inhibition of IL-6 signaling does not result in any', 'life-threatening effects either in animal models or formal toxicology studies. There is no', 'evidence from in vitro and in vivo nonclinical data to suggest that there is a risk of OKZ', 'inducing an uncontrolled biological cascade. All nonclinical data generated to date are', 'consistent with OKZ functioning as an effective antagonist of the IL-6 pathway. Cellular', 'in vitro assay data suggest that OKZ neutralizes the biological effects of IL-6 in both humans', 'Amendment 2: 06 March 2019', '24', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'and cynomolgus monkeys with similar potency. Therefore, the cynomolgus monkey is', 'considered an appropriate species to evaluate the potential toxicity of OKZ. Due to the lack', 'of activity of OKZ on IL-6 in rats and mice, the toxicology program was restricted to using a', 'single non-rodent species, the cynomolgus monkey.', 'Olokizumab is well tolerated in the cynomolgus monkey, with a no observed adverse effect', 'level (NOAEL) of 200 mg/kg/week and 50 mg/kg/week after intravenous (IV) and', 'subcutaneous (SC) administration, respectively.', 'In a study aimed at assessing the effects of OKZ on prenatal and postnatal development in', 'the cynomolgus monkey, the treatment was well tolerated during the pregnancy and had no', 'abortifacient effect. However, some OKZ-treated females experienced dystocia and', 'placental retention, sometimes associated with significant urogenital bleeding, which resulted', 'in some deaths. Given similar human and cynomolgus monkey physiology and the risk of', 'dystocia and hemorrhage at parturition, inhibition of IL-6 signaling during pregnancy is not', 'recommended.', 'Taken together, the currently completed nonclinical studies support continued clinical', 'development for marketing approval of OKZ.', '2.2.3', 'Summary of Clinical Experience', 'Nonclinical data were deemed sufficient to support clinical development of OKZ in humans', 'for the treatment of moderately to severely active RA (lead indication), other auto-immune', 'inflammatory diseases, and oncological diseases with IL-6 pathophysiology.', 'The safety, efficacy, and PK of OKZ have been investigated in 3 Phase I clinical studies', '(RA0001, RA0010, and RA0074) and 2 Phase II clinical studies (RA0056 and RA0083).', 'The safety and efficacy of OKZ were also studied in long-term open-label extension (OLE)', 'studies for both Phase II studies (RA0057 and RA0089).', 'The information in this section of the protocol regarding clinical studies with OKZ is current', 'as of 29 January 2016 (for updated information on results of clinical studies, refer to the most', \"recent version of the Investigator's Brochure).\", '2.2.3.1', 'Summary of Studies in the Olokizumab Clinical Program', 'Study RA0001', 'Study RA0001 was a Phase I, randomized, double-blind, placebo-controlled, dose-escalating,', 'first-in-human study that investigated the safety and tolerability, PK, and', 'pharmacodynamics (PD) of IV OKZ in 67 healthy Caucasian male subjects (33 on active', 'drug and 34 on placebo) with a 99-day follow-up.', 'Amendment 2: 06 March 2019', '25', 'Confidential']\n\n###\n\n", "completion": "END"}